Clinical Study Results
Research Sponsor: MedImmune LLC, a wholly owned subsidiary
of AstraZeneca
Drug Studied: MEDI0562, durvalumab, and tremelimumab
Study Title: A study to learn about the safety of MEDI0562 and
durvalumab or MEDI0562 and tremelimumab in
participants with advanced solid tumors
Thank you
Thank you for taking part in the clinical study for the study drugs MEDI0562,
durvalumab, and tremelimumab.
MedImmune sponsored this study and believes it is important to share the results.
An independent non-profit organization called CISCRP helped prepare this
summary of the study results for you.
If you participated in the study and have questions about the results, please speak
with the study doctor or staff at your study site.
Who took part in the study?
The researchers asked for the help of people with advanced solid tumors. The
participants in this study were 31 to 90 years old when they joined.
The study included 58 participants in France, the Netherlands, and the United
States.
1